PRAX Stock Analysis: Buy, Sell, or Hold?
PRAX - Praxis Precision Medicines, Inc. Common Stock
$314.00
-0.28 (-0.09%)
▼
5d:
+0.73%
30d:
+5.72%
90d:
+60.4%
BUY
MODERATE Confidence
Last Updated: January 30, 2026
Earnings: Feb 27, 2026
24d
Get Alerted When PRAX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: PRAX shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
💡 BUY OPPORTUNITY: PRAX shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
In-depth Analysis How we analyze
Valuation Analysis: PRAX is currently trading at $314.00, which is considered extended relative to its 30-day fair value range of $281.36 to $312.34.
Technical Outlook: Technically, PRAX is in a strong uptrend. Immediate support is located at $289.50, while resistance sits at $326.91.
Market Sentiment: The stock shows a mixed technical setup (55/100), with neutral trendline and momentum signals. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $512.53 (+63.2%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, PRAX is in a strong uptrend. Immediate support is located at $289.50, while resistance sits at $326.91.
Market Sentiment: The stock shows a mixed technical setup (55/100), with neutral trendline and momentum signals. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $512.53 (+63.2%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
EXTENDED
Fair Price Range
$281.36 -
$312.34
Company Quality Score
60/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
61.3%
All Signals
- BEARISH: Price extended above range
- BULLISH: Options cheap (IV 0th percentile)
- NEUTRAL: Mixed technical signals (55/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 63.2% below Wall St target ($512.53)
Fair Price Analysis
30-Day Fair Range
$281.36 -
$312.34
Current vs Fair Value
EXTENDED
Expected Move (7 Days)
±$30.03
(9.6%)
Support & Resistance Levels
Support Level
$289.50
Resistance Level
$326.91
Current Trend
Strong Uptrend
Fundamental Context
Forward P/E (Next Year Est.)
-25.00
Wall Street Target
$512.53
(+63.2%)
Revenue Growth (YoY)
1349.1%
Last updated: February 01, 2026 10:14 PM ET
Data refreshes hourly during market hours. Next update: 11:14 PM
Data refreshes hourly during market hours. Next update: 11:14 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is PRAX showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
SRPT
Sarepta Therapeutics Inc |
STRONG BUY
26 analysts |
$21 | 54 HOLD |
|
ALNY
Alnylam Pharmaceuticals … |
STRONG BUY
33 analysts |
$477 | 45 HOLD |
|
VRTX
Vertex Pharmaceuticals I… |
BUY
34 analysts |
$514 | 62 BUY |
|
IONS
Ionis Pharmaceuticals Inc |
BUY
26 analysts |
$91 | 64 BUY |
|
REGN
Regeneron Pharmaceutical… |
STRONG BUY
25 analysts |
$847 | 52 HOLD |
Advanced PRAX Option Strategies
Professional options setups generated by AI based on today's PRAX price and gamma walls.
